Webinars, Pharmaceutical

Overcoming the Challenges in Developing an In Vitro Dissolution and Release System for Orally Inhaled Drug Products

Presented by Professor Rob Price, Chief Scientific Officer, Nanopharm, An Aptar Pharma company, and Professor of Pharmaceutics at Bath University, UK, this webinar discusses how to overcome the challenges in developing an in vitro dissolution and release system for orally inhaled drug products.

April 21, 2020 5:00 PM London / 12:00 PM New York 1 Hour
watch the webinar
Presented by Pr. Rob Price
21 Apr 2020

Presenting how to overcome the challenges in developing an in vitro dissolution and release system for orally inhaled drug products

Presented by Professor Rob Price, Chief Scientific Officer, Nanopharm, An Aptar Pharma company, and Professor of Pharmaceutics at Bath University, UK, this webinar discusses how to overcome the challenges in developing an in vitro dissolution and release system for orally inhaled drug products.

Since the local drug concentrations throughout the respiratory tract cannot be measured directly, determining local bioequivalence between two products is more complicated than for systemically acting drugs. Bioavailability of the pulmonary deposited dose, both locally and systemically, is directly affected by the dissolution characteristics at the air- liquid interface. All attempts to understand dissolution differences between products have failed due to limitation in current in vitro dissolution methods.
This webinar showcases the utility of the Nanopharm UniDose and In-Vitro Release System (UniDose-IVRT) to investigate the relationship between in vitro dissolution and release characteristics of an aerosol dose. Moreover, it discusses how our UniDose-Raman system enables analysis of the microstructure of the aerosol dose and correlation to the dissolution characteristics of the drug substance.

Presented By

Pr. Rob Price

Chief Scientific Officer, Nanopharm, an Aptar Pharma Company

Prof. Rob Price is an acknowledged leader in the field of OINDPs.

Rob is the Chief Scientific Officer of Nanopharm Ltd, which is a company he founded specialising in the development of orally inhaled and nasal drug products. His research has been interfaced between engineering, pharmaceutical technology and computational pharmaceutics. He has patented several technologies and out licenced many of his inventions. Rob is a KOL in the orally inhaled and nasal drug product area and has been the recipient of several grants and contracts from the FDA’s Office of Generics.

Start a Project With Us

We Thrive on Transforming Ideas into Opportunities – Let Yours be Next.

Contact a Pharma Expert

Request Access

Close

Requesting access to Overcoming the Challenges in Developing an In Vitro Dissolution and Release System for Orally Inhaled Drug Products.

  • This field is for validation purposes and should be left unchanged.
Back To Top